2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 217-219
Technology and Procedures, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Treatment Considerations, Biological Processes, Pathogenesis, Immune Mechanism, Diseases, Bleeding and Clotting, Platelet Disorders, Thromboembolism, Thrombocytopenias, Thrombotic Disorders, Immunology, Autoimmune Disorders, Infectious Diseases, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Animal Model
PAPER

346 FVIII variants without clotting activity as potential adjunctive therapy for murine models of arterial and microvascular thormboses

Xiaxin Dong, M.S., Weixuan Chen, PhD2, Zhirong Chai, B.S.3, Wenjing Cao, MD, PhD4, Francis Ayombil, PhD5, Szumam Liu Gilbert, PhD6, Rodney Camire, PhD7, X. Frank Zhang, PhD8, X. Long Zheng, MD, PhD9
1 The University of Kansas Medical Center, Kansas City, Kansas, United States
2 University of Massachusetts Amherst, Amherst, Massachusetts, United States
3 The University of Kansas Medical Center, Kansas City, Kansas, United States
4 University of Kansas Medical Center, Kansas City, Kansas, United States
5 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
6 The University of Kansas Medical Center, Kansas City, Kansas, United States
7 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States, The University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, United States
8 University of Massachusetts Amherst, Amherst, Massachusetts, United States
9 The University of Kansas Medical Center, Kansas City, Kansas, United States

Background: Previous studies have demonstrated that coagulation factor VIII (FVIII) binds von Willebrand factor (VWF) and accelerates its proteolytic cleavage by ADAMTS13 under shear and in vivo, suggesting that FVIII may be used to treat microvascular or arterial thrombosis. However, increased levels of plasma FVIII activity are associated with venous thromboembolism, which prohibits its use for treatment.

Objectives: We engineered and expressed recombinant FVIII variants based on loss-functional mutations found in patients with hemophilia A, and determined thier VWF affinities and cofactor-dependent proteolysis of VWF by ADAMTS13 under mechanic force, as well as their therapeutic efficacy and thrombosis potential in murine models of thrombotic thrombocytopenic purpura (TTP), in conjunction with recombinant ADAMTS13.

Methods: Recombinant protein expression and purification of FVIII, VWF, and ADAMTS13 from mammalian cells, various biochemical and biophysical studies such as BLI kinetic binding and optical tweezer force induced proteolysis and conformational changes, and murine models of TTP were all employed in this study.

Results: We showed that, like wild type FVIII, recombinant FVIII variants without clotting activity (e.g., R372Q and R1689C) bound the VWF-D’D3 fragment with high affinity (KD, less than 10 nM). Addition of any FVIII variants dramatically accelerated the proteolytic cleavage of VWF by ADAMTS13 under mechanical shear with the maximal enhancing effect by 6-10 folds. Optical tweezer revealed the force-induced conformational changes and enhanced rate of cleavage of the central A2 domain upon binding to a FVIII variant. More importantly, a single dose of intravenous administration of a FVIII variant (R372Q or R1689C) with recombinant ADAMTS13 into Adamts13-/- mice significantly enhances the therapeutic efficacy in a murine model of TTP, reflected by a significantly higher platelet count and a lower level of lactate dehydrogenase activity than an administration of recombinant ADAMTS13 alone 8 hours and 24 hours following the challenge with a murine recombinant VWF.

Conclusions: FVIII variants without clotting activity bind VWF with high affinity and accelerate VWF proteolysis by ADAMTS13 under mechanical shear. These variants should be further explored for an adjunctive therapy for TTP and perhaps other arterial thrombotic disorders, without an increased risk of venous thromboembolism.

Abbreviation: FVIII, coagulation factor VIII; TTP, thrombotic thrombocytopenic purura; VWF, von Willebrand factor; ADAMTS13, a disintegrin and metalloprotease with thormobospondin type repeats, 13

Xiaxin Dong, M.S.: No relevant conflicts of interest to declare.